Journey Medical Corporation (DERM)
$5.28-7.04%Close
SELLCRISIS · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $145M
- Beta
- 1.11
- P/E (TTM)
- -23.37
- Short % float
- 20.50%
- Days to cover
- 13.9
- SI change
- +4.4%
- 1W
- -11.26%
- 1M
- -28.26%
- vs SPY 1W
- -11.12%
- vs SPY 1M
- -30.77%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 49
- VALUE
- 12
- GROWTH
- 46
- GARP
- 86
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-12.1%
REV YoY-
ROE-20.2%
EPS YoY-
ROA-6.2%
GROSS62
OP-4
NET-9
[VALUATION]
P/E TTM-23.37
P/E FWD8.82
SECTOR PE20.48
INDUSTRY PE19.11
P/B4.52
P/FCF-
EV/EBITDA77.61
EV/EBIT-
PEG0.19
FCF YIELD-
RISK
INT COV-
D/E79.53
ALTMAN Z-
CURR RATIO1.59
ND/EBITDA-
BETA1.11
Company news
FAQ
- What is LOPJLB’s current signal on DERM?
- LOPJLB’s latest quantitative signal on Journey Medical Corporation (DERM) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is DERM in?
- Journey Medical Corporation (DERM) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Journey Medical Corporation (DERM) do?
- Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyp…